Keyphrases
Adjuvant Chemotherapy
12%
Advanced Solid Tumors
10%
Atezolizumab
15%
Brain Metastases
12%
Cancer mutations
9%
Chemoradiation
11%
Chemotherapy
29%
Circulating Tumor DNA (ctDNA)
19%
Clinical Trials
12%
Confidence Interval
33%
Durvalumab
11%
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
9%
Hazard Ratio
12%
Histology
8%
Immune Checkpoint Inhibitors
14%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
34%
Lung Adenocarcinoma
9%
Lung Cancer
49%
Maximum Tolerated Dose
10%
Median Overall Survival
8%
National Cancer Database
12%
Neoadjuvant
9%
Non-small Cell Lung Cancer (NSCLC)
88%
Once-daily
9%
Overall Survival
32%
Partial Response
13%
Patient Selection
10%
Patients with Cancer
12%
Phase I Study
14%
Phase I Trial
20%
Phase II Study
30%
Phase II Trial
18%
Platinum-based Chemotherapy
11%
Previously Treated
18%
Progression-free Survival
11%
Radiation Therapy
10%
Radiotherapy
15%
Recommended Phase 2 Dose
10%
Resectable Lung Cancer
11%
Response Rate
8%
Small Cell Lung Cancer
41%
Solid Tumors
18%
Squamous Cell Lung Cancer
11%
Stable Disease
11%
Surgical Resection
10%
Surveillance Epidemiology
9%
Targeted Therapy
19%
Temsirolimus
11%
Tumor
8%
Twice Daily
9%
Medicine and Dentistry
Adenocarcinoma
5%
Adjuvant Chemotherapy
9%
Adverse Event
15%
Arm
24%
Atezolizumab
15%
Base
5%
Biological Marker
5%
Brain Metastasis
11%
Chemoradiotherapy
13%
Circulating Tumor DNA
17%
Clinical Oncology
7%
Clinical Trial
7%
Diseases
26%
Durvalumab
11%
Epidermal Growth Factor Receptor
7%
Etoposide
8%
Hazard Ratio
7%
Immune Checkpoint Inhibitor
8%
Immunotherapy
11%
Influenza Vaccination
7%
Lung
11%
Lung Adenocarcinoma
5%
Lung Cancer
56%
Malignant Neoplasm
20%
Medicine
5%
Neoadjuvant Therapy
5%
Neoplasm
26%
Next Generation Sequencing
5%
Non Small Cell Lung Cancer
100%
Non-Small Cell Lung Cancer
11%
Odds Ratio
5%
Oncology
5%
Overall Survival
38%
Phase II Trials
17%
Pneumonia
7%
Progression Free Survival
14%
Radiation Therapy
24%
Small Cell Lung Cancer
37%
Solid Malignant Neoplasm
14%
Squamous Cell Lung Carcinoma
11%
Supportive Care
5%
Surgery
23%
Surveillance, Epidemiology, and End Results
9%
Symptomatic Treatment
5%
Systemic Therapy
11%
Targeted Therapy
16%
Tyrosine-Kinase Inhibitor
7%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
15%
Antibody Drug Conjugate
6%
Antitumor Activity
7%
Biological Marker
5%
Brain Metastasis
12%
Carboplatin
8%
Chemoradiation Therapy
12%
Chemotherapy
36%
Circulating Tumor DNA
7%
Cisplatin
5%
Clinical Trial
10%
Diseases
28%
Durvalumab
11%
Ensartinib
6%
Erlotinib
5%
Etoposide
9%
Glioblastoma
5%
Immune Checkpoint Inhibitor
12%
Immunotherapy
11%
Inflammation
5%
Lung Cancer
57%
Malignant Neoplasm
24%
Maximum Tolerated Dose
7%
Neoplasm
24%
Neuroendocrine Tumor
7%
Non Small Cell Lung Cancer
70%
Overall Survival
31%
Paclitaxel
7%
Pemetrexed
7%
Pharmacokinetics
6%
Phase I Trials
12%
Phase II Trials
9%
Placebo
7%
Pneumonia
6%
Progression Free Survival
13%
Protein Tyrosine Kinase Inhibitor
9%
Small Cell Lung Cancer
36%
Solid Malignant Neoplasm
30%
Squamous Cell Carcinoma
5%
Squamous Cell Lung Carcinoma
11%
Temsirolimus
7%